BioSpace News Archive

Phase 1b Findings Presented in Oral Session at 2020 American Society of Clinical Oncology Annual Meeting Further Support CD47 as a Promising Target in First-line Higher-Risk MDS and Intensive Chemo-Ineligible AML

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new pro

Final Results from Fully Enrolled ALX148 Plus Pembrolizumab and ALX148 Plus Trastuzumab Dose Expansion Cohorts Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside the United States and Canada, to evaluate the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA® in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Silverback Therapeutics, a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, announced that preclinical data for its lead ImmunoTAC™ candidate, SBT6050, will be presented at the ASCO Virtual Scientific Program at 8:00 a.m. ET on May 29, 2020.

First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy

Results from the ongoing Phase II DESTINY-CRC01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR 2020 E-Congress, taking place virtually June 3-6, 2020. Details of the presentations are as follows: Presentation Title : B Cell Modulatory Variant TNF Receptor

TUKYSA Combination Reduced Risk of Cancer Progression in the Brain or Death by Two-Thirds, Doubled Response Rate and Reduced Risk of Death by Nearly Half Compared to Standard Therapy Alone - - Published Simultaneously in the Journal of Clinical Oncology and Presented in an Oral Session During the Virtual Scientific Program of the 2020 ASCO Annual Meeting - - First Anti-HER2 Oral Therapy in Combination with Standard Medicines to Improve Overall

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study evaluating the combination of ublituximab, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, plus ibrutinib compared to ibrutinib alone in patients with previously treated high-risk chro